Generalized Pustular Psoriasis Clinical Trial
Official title:
Multi-centre, Open-label, Expanded Access Trial of Spesolimab i.v. in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare
This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment options. Participants get a single infusion of spesolimab into a vein. They can get another spesolimab infusion one week after the first infusion if the doctors think it is helpful. Participants are in the program for about 4 months and visit the study site about 5 to 6 times. The doctors regularly check participants' health and take note of any unwanted effects.
n/a
NCT number | NCT05200247 |
Study type | Interventional |
Source | Boehringer Ingelheim |
Contact | Boehringer Ingelheim |
Phone | 1-800-243-0127 |
[email protected] | |
Status | Recruiting |
Phase | Phase 3 |
Start date | February 17, 2022 |
Completion date | March 29, 2023 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03886246 -
A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130
|
Phase 2 | |
Recruiting |
NCT05239039 -
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
Active, not recruiting |
NCT04399837 -
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
|
Phase 2 | |
Completed |
NCT03942042 -
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
|
Phase 4 | |
Completed |
NCT03782792 -
Effisayilâ„¢ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
|
Phase 2 | |
Completed |
NCT03619902 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
|
Phase 2 | |
Active, not recruiting |
NCT04566471 -
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
|
||
Recruiting |
NCT05366855 -
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
|
Phase 3 | |
Recruiting |
NCT05352893 -
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
|
Phase 3 |